-
2022-11-28
Partnership with DKSH to launch Bentrio™ Nasal Spray in Hong Kong and Macau
Nuance Pharma announces partnership with DKSH Hong Kong (DKSH HK) Business Unit Healthcare to launch BentrioTM nasal spray in Hong Kong and Macau, marking the very first milestone of Nuance
-
2022-10-28
专访优锐医药：呼吸精品特药领域，如何打造现金“造血”教科书？
近日，动脉新医药访谈了优锐医药创始人兼CEO Mark Lotter先生。Mark Lotter曾是阿斯利康的首批来华高管，拥有超过20年的中国医疗行业市场经验。Mark Lotter与我们分享了优锐医药如何练就现金“造血”能力，并逐步成长为具有差异化的特药医疗公司。
-
2022-08-18
IND Approval for Ensifentrine Pivotal Clinical Trials for COPD in China
Nuance Pharma announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal clinical trial of Ens
-
2022-07-26
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre
Nuance Pharma announces the completion of dosing for all HNVs in the Phase I clinical study of its novel Ketorolac for IV infusion (NTM-001), a non-opioid analgesic drug co-developed with N
-
2022-03-04
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced that it has entered into an exclusive licensing and distribution agreement (the "Agreement") for Bentrio™, its nasal spray for protection against airborne viruses and allergens, with Nuance Phar
-
2022-01-06
Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines
Nuance Pharma announced an agreement with Sino Health Pharmaceutical Limited to fully acquire its 100-percent equity shares and its fully-owned subsidiaries Ying Lian Zhuhai and Ying Lian Germany.
- 1
Contact PR
